



Attorney Docket No. 43962.010700

# 22C  
DB  
4/16/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hugo GEERTS, *et al.*

SERIAL NO.: 09/357,349

Group Art Unit: 1647

FILED: July 14, 1999

Examiner: Sharon L. Turner

FOR: NEUROTROPIC GROWTH FACTOR

---

**AMENDMENT AND RESPONSE UNDER 37 C.F.R 1.111**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the USPTO Office Action mailed on October 4, 2001, please reconsider the above-identified patent application in light of the following amendments and remarks. No new matter is included with these amendments.

**IN THE SPECIFICATION:**

Please amend the specification as filed with the substitute specification pages provided herein. The changes made are shown under the heading "Specification Showing Changes", while a clean copy of the amended pages is shown under the heading "Specification as Amended". No new matter has been added in this substitute specification.

**IN THE CLAIMS:**

Please amend the claims as follows. A clean copy of the amended claims is provided herein as Attachment A.

C/ 7. (Twice amended) An isolated human neurotrophic growth factor, designated enovin and having the amino acid sequence illustrated in Figure 1, [as]